Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...

The FDA on Friday approved a new biologic as add-on maintenance treatment for inadequately controlled chronic rhinosinusitis ...

In psoriasis, like cancers, disease control that includes the well-being of a patient is an additional useful measure of ...

The FDA named the first nine products to undergo a new expedited review process that takes 1 to 2 months, the agency ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

Plaque psoriasis is characterized by the formation of distinct erythematous scaly patches with clear boundaries. 1 The disease results from dysregulation of the innate and adaptive immune systems and ...

Dianthus Therapeutics (NASDAQ:DNTH) announced a licensing deal worth up to $1B with Nanjing Leads Biolabs on Thursday to ...

Instead of creating affordable products that improve health and lower costs, pharmaceutical companies focus on new drugs that will yield a healthy return on investment.

An experimental Dice Therapeutics drug in development for treating psoriasis now has its first human data showing it reduces the signs and symptoms of the inflammatory skin disorder. The preliminary ...

The Global Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size is projected to grow at a CAGR of 8.2% from 2026 to 2032, according to a new report published by Verified Market ...

Biological age and age acceleration in patients with geriatric hip fractures may predict 1-year postoperative mortality, ...